Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P00540
UPID:
MOS_HUMAN
Alternative names:
Oocyte maturation factor mos; Proto-oncogene c-Mos
Alternative UPACC:
P00540; Q3KPG9; Q3KPH0
Background:
The Proto-oncogene serine/threonine-protein kinase mos, also known as Oocyte maturation factor mos and Proto-oncogene c-Mos, plays a pivotal role in cell cycle progression and differentiation. Its kinase activity is crucial for the meiotic phase of oocyte development, marking it as a key player in reproductive biology.
Therapeutic significance:
Understanding the role of Proto-oncogene serine/threonine-protein kinase mos could open doors to potential therapeutic strategies. Its critical function in cell cycle regulation and oocyte maturation presents a unique opportunity for targeted interventions in reproductive health and oncology.